Akero Therapeutics, Inc. (AKRO)
NASDAQ: AKRO · Real-Time Price · USD
48.31
+0.28 (0.58%)
At close: Aug 13, 2025, 4:00 PM
48.54
+0.23 (0.48%)
After-hours: Aug 13, 2025, 5:03 PM EDT

Akero Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2017 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2017 - 2019
Selling, General & Admin
41.1437.9331.0729.8719.1315.27
Upgrade
Research & Development
280.35247.5141.885.2881.7664.88
Upgrade
Operating Expenses
321.48285.42172.87115.16100.8980.15
Upgrade
Operating Income
-321.48-285.42-172.87-115.16-100.89-80.15
Upgrade
Interest Expense
-4.77-4.67-3.1-0.74--
Upgrade
Interest & Investment Income
43.3438.0324.213.860.110.95
Upgrade
EBT Excluding Unusual Items
-282.91-252.06-151.76-112.03-100.78-79.21
Upgrade
Pretax Income
-283.96-252.06-151.76-112.03-100.78-79.21
Upgrade
Net Income
-283.96-252.06-151.76-112.03-100.78-79.21
Upgrade
Net Income to Common
-283.96-252.06-151.76-112.03-100.78-79.21
Upgrade
Shares Outstanding (Basic)
756753393531
Upgrade
Shares Outstanding (Diluted)
756753393531
Upgrade
Shares Change (YoY)
25.25%27.71%34.84%11.94%10.69%108.77%
Upgrade
EPS (Basic)
-3.78-3.75-2.89-2.87-2.89-2.52
Upgrade
EPS (Diluted)
-3.78-3.75-2.89-2.87-2.89-2.52
Upgrade
Free Cash Flow
-253.42-231.11-145.37-92.52-79.68-70.95
Upgrade
Free Cash Flow Per Share
-3.37-3.44-2.77-2.37-2.29-2.25
Upgrade
EBITDA
-321.46-285.41-172.84-115.11-100.85-80.14
Upgrade
D&A For EBITDA
0.030.020.030.040.040.02
Upgrade
EBIT
-321.48-285.42-172.87-115.16-100.89-80.15
Upgrade
Updated Aug 8, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q